Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Peng Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8193-8997; OpenAlex author ID A5100346763. Sources: OpenAlex.

Their work

Papers
31 (first author 8, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 4 papers · 2019: 5 papers · 2020: 7 papers · 2021: 2 papers · 2022: 5 papers · 2023: 3 papers · 2024: 2 papers

Papers 31

  1. Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target. Co-author DOI 10.1007/s00432-024-05644-2↗
  2. PELI1: key players in the oncogenic characteristics of pancreatic Cancer. Co-author DOI 10.1186/s13046-024-03008-9↗
  3. Involvement of Ataxin-3 (ATXN3) in the malignant progression of pancreatic cancer via deubiquitinating HDAC6. Co-author DOI 10.1016/j.pan.2023.06.011↗
  4. Correction for: FBXO28 promotes proliferation, invasion, and metastasis of pancreatic cancer cells through regulation of SMARCC2 ubiquitination. First author DOI 10.18632/aging.205071↗
  5. STM2457 Inhibits the Invasion and Metastasis of Pancreatic Cancer by Down-Regulating BRAF-Activated Noncoding RNA N6-Methyladenosine Modification. Co-author DOI 10.3390/cimb45110555↗
  6. FAM126A interacted with ENO1 mediates proliferation and metastasis in pancreatic cancer via PI3K/AKT signaling pathway. Co-author DOI 10.1038/s41420-022-01047-9↗
  7. Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer. Co-author DOI 10.1155/2022/7117014↗
  8. Exosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR/MAPK pathway. Co-author DOI 10.1186/s11658-022-00390-0↗
  9. RAB10 involving in glucose uptake by regulating GLUT1 predicts poor prognosis in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-1671317/v1↗
  10. Exosomal Tenascin-c Induces Proliferation and Invasion of Pancreatic Cancer Cells by WNT Signaling [Retraction]. Co-author DOI 10.2147/ott.s393902↗
  11. ICP-MS and Photothermal Dual-Readout Assay for Ultrasensitive and Point-of-Care Detection of Pancreatic Cancer Exosomes. Co-author DOI 10.1021/acs.analchem.1c02004↗
  12. Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer. Last author DOI 10.1186/s13148-021-01090-w↗
  13. Role of exosomal microRNA-125b-5p in conferring the metastatic phenotype among pancreatic cancer cells with different potential of metastasis. Co-author DOI 10.1016/j.lfs.2020.117857↗
  14. Integrated analysis identifies a pathway-related competing endogenous RNA network in the progression of pancreatic cancer. First author DOI 10.1186/s12885-020-07470-4↗
  15. Identification of dissociation factors in pancreatic Cancer using a mass spectrometry-based proteomic approach. Co-author DOI 10.1186/s12885-020-6522-3↗
  16. The miR-1224-5p/ELF3 Axis Regulates Malignant Behaviors of Pancreatic Cancer via PI3K/AKT/Notch Signaling Pathways. First author DOI 10.2147/ott.s248507↗
  17. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer. First author DOI 10.2217/epi-2019-0374↗
  18. A Prognostic Prediction Model Developed Based on Four CpG Sites and Weighted Correlation Network Analysis Identified DNAJB1 as a Novel Biomarker for Pancreatic… First author DOI 10.3389/fonc.2020.01716↗
  19. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Co-author DOI 10.7150/thno.47001↗
  20. ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. Co-author DOI 10.1016/j.yexcr.2019.03.022↗
  21. Differential secretome of pancreatic cancer cells in serum-containing conditioned medium reveals CCT8 as a new biomarker of pancreatic cancer invasion and meta… Co-author DOI 10.1186/s12935-019-0980-1↗
  22. Exosomal Tenascin-c induces proliferation and invasion of pancreatic cancer cells by WNT signaling. Co-author DOI 10.2147/ott.s192218↗
  23. Identification of RE1-Silencing Transcription Factor as a Promoter of Metastasis in Pancreatic Cancer. First author DOI 10.3389/fonc.2019.00291↗
  24. TSPAN1 upregulates MMP2 to promote pancreatic cancer cell migration and invasion via PLCγ. Co-author DOI 10.3892/or.2019.6989↗
  25. Pancreaticoduodenectomy is justified in a subset of elderly patients with pancreatic ductal adenocarcinoma: A population-based retrospective cohort study of 4,… Co-author DOI 10.1016/j.ijsu.2018.03.054↗
  26. Exosomal zinc transporter ZIP4 promotes cancer growth and is a novel diagnostic biomarker for pancreatic cancer. First author DOI 10.1111/cas.13737↗
  27. Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics. Co-author DOI 10.2147/ott.s162470↗
  28. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathw… Co-author DOI 10.3727/096504018x15166223632406↗
  29. Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium. Co-author DOI 10.1038/srep37606↗
  30. Phosphoproteome Analysis of Invasion and Metastasis-Related Factors in Pancreatic Cancer Cells. First author DOI 10.1371/journal.pone.0152280↗
  31. CA724 is a novel factor for predicting the unresectability in pancreatic adenocarcinoma. Co-author PMID 26823852↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tan · 20 shared papers, 2016–2022 · strength 2.37
  2. Lingming Kong · 8 shared papers, 2019–2022 · strength 1.10
  3. Yaozhen Pan · 4 shared papers, 2022–2024 · strength 0.78
  4. Xinlu Liu · 6 shared papers, 2018–2022 · strength 0.71
  5. Haoyi Jin · 7 shared papers, 2016–2020 · strength 0.69
  6. Yunhao Wu · 7 shared papers, 2016–2020 · strength 0.69
  7. Xiaobin Fei · 3 shared papers, 2023–2024 · strength 0.61
  8. Songbai Liu · 3 shared papers, 2022–2024 · strength 0.55
  9. Likun Ren · 2 shared papers, 2024 · strength 0.44
  10. Songying Qian · 3 shared papers, 2018–2022 · strength 0.42
  11. Keke Liang · 3 shared papers, 2020 · strength 0.38
  12. Mengwei Wu · 4 shared papers, 2016–2020 · strength 0.35
  13. Fuqiang Zu · 2 shared papers, 2020–2022 · strength 0.33
  14. Yunhao Wu · 2 shared papers, 2019–2022 · strength 0.33
  15. Xiaobo Zhang · 3 shared papers, 2016–2019 · strength 0.27
  16. Yao Wang · 1 shared paper, 2023 · strength 0.26
  17. Xin Wu · 1 shared paper, 2023 · strength 0.26
  18. Yifan Yang · 3 shared papers, 2016–2020 · strength 0.26
  19. Bing Song · 2 shared papers, 2019–2020 · strength 0.24
  20. Shaojie Chen · 1 shared paper, 2024 · strength 0.23
  21. Xiaoli Yin · 1 shared paper, 2021 · strength 0.22
  22. Yang Gao · 2 shared papers, 2019–2020 · strength 0.22
  23. Xing Wang · 1 shared paper, 2024 · strength 0.21
  24. Yongjia Gao · 1 shared paper, 2024 · strength 0.21
  25. Shaolong Hao · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.